COVID-19
Conditions
Interventions
Clinical Study, Randomized, Triple blind, Placebo-Controlled
Intervention group: 25 adult individuals hospitalized due to Covid-19, of both sexes, will receive Bryonia alba in 30 CH, 200 CH and 1000
HP4.018.158.773
Sponsors
Hospital Regional de Mato Grosso do Sul
Universidade Federal de Mato Grosso do Sul
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Men and women at least 18 years older with confirmed disease with positive SARS-CoV-2 molecular test (RT-PCR) admitted at Hospital Regional de Mato Grosso do Sul ward with at least one of the following conditions: oxygen saturation less than 95% in ambient air; signs of respiratory discomfort or rise in respiratory frequency evaluated according to age; worsening of underlying disease clinical conditions; hypotension; fespiratory insufficiency.
Exclusion criteria
Exclusion criteria: Viral infections wiht etiological agents other than SARS-CoV-2; negative SARS-CoV-2 molecular test (RT-PCR); other diseases with respiratory tract impairment with negative SARS-CoV-2 molecular test (RT-PCR); need of special treatment and care, such as pregnant women and severe comorbidities (cardiovascular disease, cancer, imunosuppression, HIV and tuberculosis, among others).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We expect that the group receiving active homeopathic medicine as complementary therapy will have a more favorable resolution of Covid-19, which will be verified by smaller number of days until the patient is discharged, and for a smaller number of participants belonging to the active group that die or have clinical aggravation requiring transference to the Hospital's Intensive Care Unit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are not expected. | — |
Countries
Brazil
Contacts
Public ContactIago Caires
Outcome results
None listed